Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled Trial

<p>Introduction: Patients with advanced hepatocellular carcinoma (HCC) face an extremely poor prognosis. Sorafenib, a multikinase inhibitor, remains an essential treatment for advanced HCC in certain clinical settings where immunotherapy is either contraindicated or unavailable. However,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yan Zhao, Wei Bai, Rong Ding, Nan You, Lin Zheng, Lei Li, Jianbing Wu, Peng Zhang, Wukui Huang, Hui Zhang, Yongjin Zhang, Diwen Zhu, Haiping Li, Dongdong Xia, Jie Yuan, Xiaomei Li, Zhengyu Wang, Bohan Luo, Wengang Guo, Zhanxin Yin, Wei Mu, Ming Huang, Jing Li, Weixin Ren, Daiming Fan, Yong Lv, Guohong Han
Format:	Artigo
Idioma:	Inglês
Publicat:	Karger Publishers 2026-01-01
Col·lecció:	Liver Cancer
Accés en línia:	https://karger.com/article/doi/10.1159/000546530
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!